Metacrine Inc MTCR

NAS: MTCR | ISIN: US59101E1038 20/06/2023

0,581 USD (-1,29%)

(-1,29%) 20/06/2023

Grafiek Metacrine Inc

Grafiek Metacrine Inc

1 dag1d -1,29%
1 week1w 0,00%
1 maand1m 0,00%
3 maanden3m 0,00%
6 maanden6m 0,00%
1 jaar1j 4,83%
5 jaar5j -95,06%

Metacrine Inc in het nieuws

Toon enkel gratis nieuws

18 maart 2021 · Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results · Persbericht

11 maart 2021 · Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference · Persbericht

11 maart 2021 · Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call · Persbericht

9 maart 2021 · Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH · Persbericht

2 maart 2021 · Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference · Persbericht

19 februari 2021 · Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference · Persbericht

16 februari 2021 · Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology · Persbericht

19 januari 2021 · Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH · Persbericht

5 januari 2021 · Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH · Persbericht

Profiel Metacrine Inc

Gezondheidstechnologie

Werknemers: 32

Aandelen Metacrine Inc

Beurswaarde: 24,75 miljoen USD

Effecten: 42,57 miljoen

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe